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A B S T R A C T
Background: Neuropsychiatric symptoms (NPS) are common in Alzheimer’s disease (AD) and are
associated with admission to institutional care. Current guidelines recommend non-pharmacological
interventions as the ﬁrst-line treatment for NPS. However, high-quality randomized studies focused on
NPS are scarce. The objective here was to examine whether a regular and long-term exercise programme
either at home or as a group-based exercise at an adult day care centre has beneﬁcial effects on AD
patients’ NPS or permanent institutionalizations.
Design, setting, and participants: A randomized, controlled trial with 210 community-dwelling AD
patients.
Intervention: Two types of intervention comprising (1) group-based exercise in day care centres (GE) and
(2) tailored home-based exercise (HE), both twice a week for 12 months, were compared with (3) a
control group (CG) receiving usual community care.
Measurements: NPS were measured with the Neuropsychiatric Inventory (NPI) at baseline and 6 months,
and depression with the Cornell Scale for Depression in Dementia (CSDD) at baseline and 12 months.
Data on institutionalizations were retrieved from central registers.
Results: No signiﬁcant differences between the groups were detected in NPI at 6 months or in CSDD at
12 months when analyses were adjusted for age, sex, baseline Clinical Dementia Rating, and Functional
Independence Measure. There was no difference in admissions to permanent institutional care between
the groups.
Conclusions: Regular, long-term exercise intervention did not decrease NPS in patients with AD.




Neuropsychiatric symptoms (NPS), such as agitation, anxiety,
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core symptoms; cognitive and functional decline. NPS are often
associated with a lower quality of life, higher caregiver distress,
poor prognosis, earlier institutionalization, and increasing health
care costs [1,2]. Of patients with dementia, 80–90% suffer from
these symptoms at some point during disease progression [3,4]. In
the MAASBED longitudinal study, 65% of dementia patients with
NPS at baseline continued to have at least one symptom during the
two-year follow-up [3]. Occurrence of the NPS may be persistent or
intermittent, complicating their prevention and treatment.
Researchers have suggested that NPS in dementia can be
divided into clusters of symptoms or subsyndromes that may differy. All rights reserved.
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minor differences in the studies exist, deﬁnitions of the subsyn-
dromes of hyperactivity, mood, and psychosis are in general
agreement and supported by clinical evidence [4–6]. Treatment
interventions may be more beneﬁcial when targeting subsyn-
dromes rather than individual symptoms [5].
Traditionally, psychotropic medication, especially antipsychot-
ic drugs, has been used to alleviate NPS. However, the beneﬁts are
often modest and must be carefully weighed against the risk of
adverse effects [7,8]. Current guidelines recommend non-phar-
macological methods as the ﬁrst-line treatment approach for NPS
(Nice guideline 2016). The non-pharmacological treatments
comprise various behavioural, environmental, and care giver
supportive interventions. Evidence supporting beneﬁcial treat-
ment effects of these therapies has been accumulating during
recent years. Still, high-quality randomized studies on non-
pharmacological treatments strategies for NPS in AD are few [9].
Over the last decades a considerable amount of evidence has
accumulated of the effects of exercise as preventive or even
disease-modifying treatment of age-related dementia. The positive
effects are thought to be mediated through improvement of
cerebrovascular circulation, stimulation of angiogenesis and
neurogenesis, and controlling the inﬂammation processes [10].
It is also possible that such mechanisms as improved well-being
and self-esteem, as well as increased social contacts may generate
symptomatic relief as a result of exercise in dementia patients [11].
Physical exercise may improve mood and sleep and reduce
depressive symptoms in healthy older adults [12,13]. Moreover, a
physically active lifestyle in dementia patients has been shown to
be associated with a lower frequency of NPS [14]. However,
ﬁndings of the effects of exercise intervention on NPS in dementia
patients from clinical studies and meta-analyses have so far been
inconsistent [15,16]. Positive effects of exercise have been found to
be more pronounced in some symptoms (depression, agitation,
wandering, sleep) than in others (anxiety and apathy) [17]. Accord-
ing to a recent meta-analysis, depression and aberrant motor
behaviour appear to be the NPS most positively affected by
exercise. However, the effects on global NPI scores have been
insigniﬁcant [15]. A substantial heterogeneity has been found in
the types of exercise used in the intervention studies; aerobic,
resistance training and mixed exercise being the most widely used.
Recent Cochrane review was not able to give a recommendation of
what type of exercise, or at what frequency or duration would the
most beneﬁcial for patients with dementia [16].
The objective of this study was to examine whether regular,
long-term exercise has beneﬁcial effects on depression and other
NPS in patients with AD. We also examined the impact of exercise
on admissions to permanent institutional care.
2. Methods
2.1. Study design
This paper reports secondary ﬁndings of a randomized
controlled study, FINALEX, which examined the effects of exercise
intervention on AD patients’ physical performance, cognition, and
NPS [18]. Community-dwelling older adults with AD were
randomly allocated into two intervention groups or a control
group. The exercise sessions were administered by a physiothera-
pist either at participants’ homes (home-exercise group, HE) or at
day care centres (group-exercise group, GE) for 60 minutes twice a
week for 12 months. The controls (CG) continued with normal
community care. The study protocol was approved by the Ethics
Committee of Helsinki University Central Hospital. A detailed
description of the design and endpoints of the FINALEX study has
been provided earlier [18].This article evaluates the effects of exercise on NPS, depression,
and institutionalizations in AD patients.
2.2. Participants
Patients over 65 years of age living with a spouse in the Helsinki
area and who were listed on the AD drug reimbursement register of
the Social Insurance Institution of Finland were invited to
participate in this trial. Patients in this register are diagnosed
with AD according to the NINCD-ADRDA criteria [19] evaluated by
a geriatrician/neurologist.
Individuals showing an interest in participating were assessed for
additional inclusion criteria: ability to walk independently with or
without a mobility aid, no terminal illness, and at least one sign of
frailty (one or more falls during the last year, decreased walking
speed, or unintentional weight loss). Altogether 210 patient-carer
dyads fulﬁlled all inclusion criteria and were enrolled in the study.
Each participant and spousal care giver gave informed, written
consent. If the patient’s judgement capacity was reduced, the spouse
provided consent on behalf of the patient. All patients randomized
into one of the exercise groups underwent a thorough medical
examination by a geriatrician to ensure safety of the intervention.
2.3. Measures
We used the Neuropsychiatric Inventory (NPI) to assess NPS.
The NPI evaluates 12 neuropsychiatric disturbances frequently
seen in dementia: delusions, hallucinations, agitation, dysphoria,
anxiety, apathy, irritability, euphoria, disinhibition, aberrant
motor behaviour, night-time behaviour disturbances, and appetite
and eating abnormalities. For each symptom, the severity is
multiplied by the frequency, with the summed score providing the
total NPI score. The score ranges from 0 (no NPS) to 144 (the
highest number and most severe symptoms). The validity and
reliability of NPI have been established, and it has also been found
to be fairly sensitive [20]. A trained nurse administered the NPI to
the spousal informant at baseline and 6 months.
In addition to NPI scores, we investigated the effects of
intervention on behavioural subsyndromes. We categorized the
individual symptoms into subgroups of ‘‘Hyperactivity’’ (agitation,
aggressiveness, disinhibition, irritability, aberrant motor behav-
iour), ‘‘Mood and apathy’’ (depression, anxiety, euphoria, apathy,
sleeping problems, eating problems), and ‘‘Psychosis’’ (hallucina-
tions, delusions) according to Aalten and co-workers [5].
We evaluated depressive symptoms with the Cornell Scale of
Depression in Dementia (CSDD) [21] at baseline and 12 months. In
CSDD, the information is obtained by interviewing the caregiver
and by observing and interviewing the patient. The scale contains
19 items with a maximum score of 38 and a score > 10 indicating
depression. This scale has good sensitivity and speciﬁcity and has
been validated in populations of dementia patients [22].
The stage of dementia was assessed with Clinical Dementia
Rating [23], and the Charlson Comorbidity Index [24] was
calculated to measure the overall disease burden. At baseline,
the demographic data and medical history were collected.
Evaluations of physical functioning were done with Functional
Independence Measure (FIM), and cognition with Mini Mental
Stage Examination. The participants were followed for two years
for use of nursing homes. Data on admissions to permanent
institutional care were retrieved from central registers.
2.4. Randomization
The participants were randomized after the baseline visit. A
separate randomization centre was used to assign the patient-
spouse dyads (n = 210) into three groups of equal size (n = 70):
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 group-based exercise (GE);
 and a control group (CG).
2.5. Interventions
Both intervention groups exercised under supervision of a
physiotherapist for 60 minutes twice a week for 12 months. The
exercise sessions consisted of aerobic exercise, strength training,
balance training, and dual-tasking. Fifteen minutes was allocated
to each exercise domain. The intensity of the training was
gradually increased, and the balance and dual-task exercises were
made more demanding during the intervention phase [25].
In the HE group, the training was individually tailored to meet
the needs of the participant and the sessions took place at the
participant’s home. Aerobic exercises included Nordic walking and
training with a restorator bike. Wrist and ankle weights were used
to assist the strength training. Balance exercises consisted of stair
climbing, picking up items from the ﬂoor, and getting up from the
ﬂoor. Talking while walking, singing while training, and perform-
ing two different functions with the left and right hands while
counting numbers forward or backward are examples of the dual-
task exercises.
The GE group exercised in groups of 10 supervised by two
physiotherapists in day care centres. The visits to day care centres
lasted 4 hours and included door-to-door taxi service, lunch, and
coffee breaks. Actual training time was 60 minutes and consisted
of components similar to those described for the HE group. The
strength training was, however, assisted with gym equipment.
The control group continued in usual care, but was entitled to
physiotherapy provided by the communal health care system if
needed. All participants and care givers were also given oral and
written information on exercise and nutrition.
2.6. Statistical analyses
Statistical comparison between groups was conducted using
analysis of variance (ANOVA), Kruskal-Wallis test, and Chi2 test, as
appropriate. When adjusting for confounding factors (age, sex,
baseline CDR and FIM), analysis of covariance or logistic regression
model was applied. In the case of violation of assumptions (e.g.
non-normality), a bootstrap-type test was used. Effect size (‘‘d’’)Table 1
Baseline characteristics of Alzheimer’s disease patients.
Group exercise, n = 57 
Age, mean (SD) 77.9 (5.2) 
Men, n (%) 37 (64.9) 
Education < 8 years, n (%) 18 (31.6) 
CDR, n (%) 
0.5 6 (10.5) 
1 15 (26.3) 
2 30 (52.6) 
3 6 (10.5) 
MMSE, mean (SD) 18.9 (6.5) 
On AD medication, n (%) 57 (100) 
On psychotropic medication, n (%) 20 (35) 
FIMtot, mean (SD) 90.1 (17.6) 
Cornell, mean (SD) 3.9 (3.5) 
NPI tot, mean (SD) 12.1 (9.8) 
Hyper 4.3 (6.3) 
Psych 1.3 (2.3) 
Mood 8.1 (5.7) 
Charlson comorbidity index, mean (SD) 2.4 (1.6) 
SD: standard deviation; CDR: Clinical Dementia Rating; AD: Alzheimer’s disease; AChEI
Measure (tot: total score); Cornell: Cornell Scale for Depression; NPI: Neuropsychiatric Inv
Mood and Anxiety subsyndrome); Psychotropic medication (ATC codes N05A, N05B, N
a Differences between the groups were tested by x2 test for categorical variables anwas calculated by using the method of Cohen for paired samples
(mean follow-up scores minus baseline scores, divided by the
pooled standard deviation). Effect size of 0.20 was considered
small, 0.50 medium, and 0.80 large. Conﬁdence intervals for the
effect sizes were obtained by bias-corrected bootstrapping
(5000 replications). STATA 14.1, StataCorp LP (College Station,
TX, USA) statistical package was used for the analyses.
3. Results
The study groups were similar in baseline characteristics. (Table
1). Patients’ mean age was 77.8 years, and 61.5% were men. Two in
three suffered from advanced dementia (CDR 2–3), and 97.8% were
on AD medication. Participants also had several other medical
conditions, the mean Charlson comorbidity index being 2.5.
At baseline, 38% of the participants were on psychotropic
medication. One in four was on an antidepressive (ATC code N06),
and one in ten on an antipsychotic medication (ATC code N05A).
The proportion using benzodiazepines regularly or intermittently
was 16% (Table 1).
3.1. Effects of exercise intervention on neuropsychiatric symptoms
The NPI was administered at baseline and 6 months. Of the
210 participants, 179 had complete NPI data from baseline and
6 months, and thus, were included in the analyses. Almost 100% of
the participants had one or several NPS throughout the study. The
most frequently occurring single NPS was apathy, with 96% of the
participants suffering from at least some degree of this symptom
during the study.
At baseline, the mean NPI scores were fairly low: in HE, the
mean NPI was 13.5, in GE 12.1, and in CG 16.6. At 6 months, no
signiﬁcant changes in total NPI or individual symptom scores were
detected (Table 2). In GE, a minor decrease in irritability scores was
seen, 0.49 (95% CI: 0.99 to 0.54, P = 0.03). When examining the
effects of exercise on symptom subgroups, the effect sizes
remained below statistical or clinical signiﬁcance (Fig. 1).
3.2. Effects of exercise intervention on depression
The Cornell Scale of Depression in Dementia (CSDD) was
utilized for 149 participants at baseline and 12 months. The
changes over 12 months were modest: In GE 1.35 (95% CI: 0.14 toHome exercise, n = 63 Control, n = 59 P-valuea
77.4 (5.3) 78.1 (5.3) 0.72
39 (61.9) 34 (57.6) 0.72
25 (40.3) 25 (42.4) 0.45
0.46
4 (6.3) 1 (1.7)
18 (28.6) 20 (33.9)
30 (47.6) 31 (52.5)
11 (17.5) 7 (11.9)
18.6 (6.2) 17.8 (6.0) 0.60
61 (96.8) 57 (96.6) 0.38
27 (43) 21 (36) 0.61
88.9 (18.4) 89.1 (18) 0.92
4.8 (4.7) 5.9 (5.7) 0.23
13.5 (12.6) 16.6 (15.2) 0.33
5.1 (7.4) 6.1 (7.5) 0.28
1.6 (2.9) 2.8 (5.2) 0.36
8.3 (6.2) 9.6 (7.6) 0.56
2.4 (1.6) 2.7 (1.6) 0.42
: acetylcholinesterase inhibitor; Mem: memantine; FIM: Functional Independence
entory (Hyper: Hyperactivity subsyndrome; Psych: Psychosis subsyndrome; Mood:
05C, N06).
d Kruskal-Wallis test for continuous, non-normally distributed variables.
Table 2
Changes in the Neuropsychiatric Inventory (NPI) [18] scores relative to baseline in the intervention and control groups. Negative points in changes indicate less
neuropsychiatric symptoms at 6 months.
Baseline, mean (SD) Change from baseline, mean (95% CI) P-value*
Group exercise Home exercise Control Group exercise Home exercise Control
Hyperactivity 4.33 (6.34) 5.05 (7.41) 6.12 (7.45) 0.23 (1.69 to 0.97) 1.42 (0.25 to 2.78) 0.14 (1.45 to 1.7) 0.13
Agitation, aggression 1.18 (2.16) 1.27 (1.97) 1.58 (2.39) 0.19 (0.72 to 0.29) 0.21 (0.23 to 0.66) 0.02 (0.70 to0.68) 0.27
Disinhibition 0.81 (2.44) 0.89 (2.67) 0.69 (1.85) 0.49 (1.24 to 0.15) 0.03 (0.57 to 0.65) 0.25 (0.55 to0.18) 0.24
Irritability 1.28 (2.43) 1.35 (2.57) 1.39 (2.24) 0.46 (0.99 to 0.54) 0.13 (0.25 to 0.69) 0.34 (0.18 to 0.83) 0.03
Aberrant motor behaviour 1.07 (2.03) 1.53 (2.62) 2.46 (3.51) 0.91 (0.22 to 1.59) 1.05 (0.29 to 1.86) 0.03 (0.88 to 0.96) 0.65
Psychosis 1.33 (2.28) 1.61 (2.88) 2.75 (5.15) 0.46 (0.67 to 1.09) 0.74 (0.34 to 1.66) 0.27 (1.00 to 1.39) 0.81
Delusions 0.89 (1.96) 1.02 (2.24) 1.49 (2.84) 0.18 (0.40 to 0.63) 0.52 (0.19 to1.03) 0.51 (0.24 to 1.26) 0.31
Hallucinations 0.44 (1.05) 0.60 (1.41) 1.25 (2.55) 0.28 (0.03 to 0.67) 0.23 (0.24 to 0.73) 0.24 (0.85 to0.35) 0.97
Mood and apathy 8.07 (5.71) 8.27 (6.23) 9.63 (7.61) 1.25 (0.55 to 3.21) 0.40 (1.16 to 2.03) 0.31 (1.38 to 2.12) 0.76
Depression 0.89 (1.45) 1.15 (1.92) 1.59 (2.55) 0.11 (0.23 to 0.48) 0.05 (0.71 to 0.54) 0.07 (0.69 to0.55) 0.90
Anxiety 0.96 (2.18) 1.06 (2.39) 1.51 (2.34) 0.05 (0.72 to 0.55) 0.03 (0.53 to 0.53) 0.49 (1.24 to 0.20) 0.79
Euphoria 0.18 (0.57) 0.35 (1.60) 0.31 (1.64) 0.11 (0.07 to 0.34) 0.08 (0.36 to 0.14) 0.10 (0.33 to0.67) 0.33
Apathy 4.12 (2.3) 4.24 (2.19) 4.32 (2.51) 0.40 (0.19 to 0.97) 0.69 (0.11 to 1.34) 0.83 (0.13 to 1.71) 0.33
Sleeping problems 0.96 (2.38) 0.66 (1.70) 0.97 (2.50) 0.37 (0.26 to 1.05) 0.29 (0.34 to 1.03) 0.51 (0.88 to 1.05) 0.84
Eating problems 0.84 (2.46) 0.81 (2.15) 0.93 (2.34) 0.03 (0.53 to 1.24) 0.48 (0.98 to 0.10) 0.08 (0.79 to 0.98) 0.04
NPI total 12.05 (9.77) 13.45 (12.61) 16.56 (15.20) 0.88 (1.30 to 2.84) 2.73 (1.08 to 5.05) 0.64 (2.23 to 3.46) 0.41
* Adjusted for baseline age, sex, Clinical Dementia Rating (CDR), and Functional Independence Measure (FIM).
Fig. 1. Effect sizes of changes in neuropsychiatric subsyndromes in persons with
Alzheimer’s disease. Positive Effect size indicates a decrease in Neuropsychiatric
Inventory (NPI) [18] scores (improvement), whereas negative Effect size indicates
an increase in NPI scores (worsening). Effect size of 0.20 was considered small,
0.50 medium, and 0.80 large. ‘‘Hyperactivity’’ (agitation, aggressiveness,
disinhibition, irritability, aberrant motor behaviour), ‘‘Mood and apathy’’
(depression, anxiety, euphoria, apathy, sleeping problems, eating problems), and
‘‘Psychosis’’ (hallucinations, delusions), ‘‘Total’’ (total score of the NPI) [5].
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1.56 to 1.40). The differences between the groups were not
signiﬁcant (P = 0.81, adjusted by age, sex, baseline CDR and FIM).
3.3. Effects of exercise intervention on institutionalizations
Thirteen participants were permanently institutionalized in
each of the intervention groups, whereas the respective ﬁgure in
the control group was 11 (P = 0.79, adjusted by age, sex, baseline
CDR and FIM).
4. Discussion
Among patients with AD, an exercise intervention, which had
achieved positive results on physical performance and cognition
previously [25,26], had no signiﬁcant effect on NPS, measured by
the NPI after 6 months of exercise training, or on depression,
measured by the CSDD after 12 months of exercise training.
Neither could we show any effect on rate of institutionalizations.
The results of this study are in line with earlier studies where
exercise as a single intervention was unable to reduce NPS in
dementia patients [27,28]. A fairly large study among home-
dwelling dementia patients did not ﬁnd positive effects on
behavioural symptoms measured with the NPI after 12 weeks of
regular walking sessions [28]. Similar results were obtained in aChinese study where dementia patients practised Tai Chi three
times a week for 12 weeks [27]. The best effects in reducing NPS in
dementia patients have thus far been achieved by tailoring
multicomponent interventions for the patients combining exercise
with, for example, support and educational programmes for the
carers [8,29].
A strength of this study is its sound methodology. All
participants had an established AD diagnosis, and the intervention
was performed twice weekly for a year by well-trained physio-
therapists. There was good compliance among AD participants
[25], and the outcome measures were valid. The exercise
interventions were simple and could be easily implemented in
primary care. However, some limitations should be recognized
when interpreting the results of this study. The power calculations
were based on physical performance measured with the Functional
Independence Measure (FIM). Neuropsychiatric measures were
only secondary endpoints of the study. The primary focus being on
physical performance, the timing and extent of the neuropsychi-
atric measures may be considered suboptimal. Moreover, the
participants were motivated volunteers living in their own homes
with a spouse, and thus, generalizing the results to other patient
groups should be done with caution.
Several explanations may be offered for the results in
neuropsychiatric measures not reaching statistical signiﬁcance,
although a positive trend was seen. The primary outcome of this
study was physical performance. Hence, the interventions were
not aimed at decreasing NPS in general. In previous studies with
positive results, the objective has often been to explore a single
NPS and the effects of an intervention targeted to reduce this
particular symptom such as depression or apathy [30,31]. It has
also been shown that different NPS, e.g. motor hyperactivity and
apathy, can occur simultaneously in dementia, perhaps needing a
different clinical approach [32]. The participants of our study were
volunteers from the community who lived with a carer, and
thereby, may reﬂect a lower probability of NPS. Patients with more
severe symptoms and their carers may be less keen to participate
in an intervention study. The NPS scores were relatively low at
baseline, thus, there was a ﬂoor effect in reducing NPS.
Furthermore, 99% of the patients were on Alzheimer’s medication,
which may alleviate the NPS. A large percentage of the participants
used psychotropic medication at the beginning of the study,
possibly distorting the results. Abundant use of psychotropic
medication can also reﬂect the current need for more safe and
effective treatment of NPS in dementia. We did not collect data on
use of psychotropic medication post-intervention so we are unable
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decreasing the use of these potentially harmful medications. This
aspect has been only marginally explored previously [15], and
further studies are needed.
Frequent NPS in dementia are often the leading cause of early
institutionalization [2]. In this study, we were unable to show
beneﬁcial effects of exercise on NPS, which may, to some degree,
explain the non-existent effects on the rate of permanent care
placement. Exercise as a single intervention may be insufﬁcient to
overcome the wide spectrum of individual medical, psychological,
and social factors leading to NPS and permanent institutionaliza-
tion. Further evaluations are required to determine the best
combinations of non-pharmacological interventions for various
patient groups and symptom clusters.
5. Conclusions
The 12-month exercise intervention showed no positive effects
on neuropsychiatric symptoms in patients with Alzheimer’s
disease.
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